Oseltamivir acid: Potent Influenza Neuraminidase Inhibitor and Oncology Tool

Executive Summary: Oseltamivir acid is the active metabolite of the prodrug oseltamivir and is a direct-acting neuraminidase inhibitor with high solubility in DMSO, water, and ethanol (APExBIO, Oseltamivir acid product page). It blocks the sialidase activity of influenza neuraminidase, preventing viral egress and reducing influenza propagation in vitro and in vivo. The compound demonstrates dose-dependent inhibition of sialidase activity and cell viability in breast cancer cell models and shows synergy with chemotherapeutic agents. In mouse xenograft models, intraperitoneal administration of 30–50 mg/kg significantly reduces tumor vascularization and metastasis. Resistance is associated with specific neuraminidase mutations, notably H275Y (Yang et al, 2025).

Biological Rationale

Oseltamivir acid is the hydrolyzed, active form of the prodrug oseltamivir, produced by carboxylesterase activity in the intestine and liver (Yang et al, 2025). Neuraminidase is an essential surface glycoprotein of influenza viruses, catalyzing the cleavage of terminal sialic acids from host and viral glycoconjugates. This enzymatic process enables the release of progeny virions from infected cells and facilitates further infection cycles. Blocking neuraminidase activity interrupts viral propagation and reduces disease severity (Oseltamivir Acid: Benchmark Influenza Neuraminidase Inhibitor). The role of sialidases extends to non-viral systems, with implications in cancer cell migration, invasion, and metastasis, thereby broadening research applications for oseltamivir acid (Oseltamivir Acid: Advanced Influenza Neuraminidase Inhibitor).

Mechanism of Action of Oseltamivir acid

Oseltamivir acid is a competitive inhibitor of influenza neuraminidase. It binds to the active site of the enzyme, mimicking the transition state of the sialic acid substrate. This interaction disrupts the cleavage of α-Neu5Ac (N-acetylneuraminic acid) residues from the glycoproteins on newly formed virions. The blockade prevents the release of viral particles from infected cells, thereby containing infection spread (APExBIO). The inhibition is reversible and concentration-dependent. In cancer models, inhibition of sialidase activity is linked to the suppression of tumor cell motility and metastatic potential.

Evidence & Benchmarks

• Oseltamivir acid is generated from oseltamivir by intestinal and hepatic esterases in both human and animal systems (Yang et al, 2025).
• The compound is soluble at ≥14.2 mg/mL in DMSO, ≥46.1 mg/mL in water (with gentle warming), and ≥97 mg/mL in ethanol (with gentle warming) (APExBIO).
• In vitro, oseltamivir acid demonstrates dose-dependent reduction of sialidase activity and cell viability in MDA-MB-231 and MCF-7 breast cancer cell lines (Oseltamivir acid (SKU A3689): Reliable Neuraminidase Inhibitor).
• Combination with chemotherapeutic agents (Cisplatin, 5-FU, Paclitaxel, Gemcitabine, Tamoxifen) yields enhanced cytotoxic effects in breast cancer models (Oseltamivir Acid: Benchmark Influenza Neuraminidase Inhibitor).
• Intraperitoneal dosing at 30–50 mg/kg in RAGxCγ double mutant mice with MDA-MB-231 xenografts results in significant inhibition of tumor vascularization, growth, and metastasis, with higher doses achieving complete ablation of tumor progression and improved animal survival (APExBIO).
• Resistance to oseltamivir is linked to mutations in the neuraminidase gene, especially H275Y (Yang et al, 2025).

Applications, Limits & Misconceptions

Oseltamivir acid serves as a reference agent for influenza virus replication inhibition and antiviral drug development. Its well-characterized mode of action also supports its use as a chemical probe in cancer metastasis inhibition studies. The compound is recommended for use in both influenza infection models and oncology workflows, particularly where sialidase activity is a mechanistic target.

Common Pitfalls or Misconceptions

• Oseltamivir acid is not effective against non-influenza viruses: It specifically inhibits influenza virus neuraminidase and shows no activity against neuraminidases from unrelated viral families.
• Resistance due to H275Y mutation: Mutations in the neuraminidase gene, such as H275Y, confer reduced sensitivity to oseltamivir acid (Yang et al, 2025).
• Instability in solution: Long-term storage of oseltamivir acid solutions is discouraged; prepare fresh aliquots and store at -20°C to preserve stability (APExBIO).
• Species-specific metabolism: Esterase-driven conversion rates differ across species, impacting pharmacokinetics and efficacy. Humanized mouse models provide the closest in vivo-in vitro correlation (Yang et al, 2025).
• Limited in vivo anticancer efficacy in non-breast cancer models: Preclinical data supporting metastasis inhibition are currently limited to breast cancer models; generalization requires further research.

Workflow Integration & Parameters

Oseltamivir acid (SKU A3689) from APExBIO is supplied as a research-grade solid for in vitro and in vivo applications (product page). For cell-based assays, dissolve in DMSO, water, or ethanol as per solubility data. For animal studies, intraperitoneal injection is effective at 30–50 mg/kg. Avoid repeated freeze-thaw cycles and store stock at -20°C. In influenza antiviral research, use as a positive control for neuraminidase inhibition (Oseltamivir Acid: A Neuraminidase Inhibitor for Influenza). In oncology workflows, combine with established chemotherapeutics for synergy studies. This article extends previous guidance by detailing benchmarks and resistance mechanisms, complementing the troubleshooting focus of this scenario-based resource.

Conclusion & Outlook

Oseltamivir acid is a potent, well-documented neuraminidase inhibitor with validated protocols for both virology and oncology research. Its use is supported by robust in vitro and in vivo data, with clear guidelines for solubility, storage, and resistance monitoring. Ongoing studies will clarify broader oncology applications and guide resistance management strategies. For further details and optimized workflows, consult the APExBIO Oseltamivir acid data sheet and related technical resources.